All In Biotech

Drug Trial Radar · NCT05512598

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Multi-centre, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of HB0034 in Patients Acute Generalized Pustular Psoriasis (GPP) Flare

Last checked: Nov 19, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Nov 6, 2022

Primary completion

Nov 15, 2023

Study completion Jan 10, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP ).

Conditions

  • Generalized Pustular Psoriasis

Interventions

  • HB0034Drug

    HB0034, a single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with drug related adverse eventsTime frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Shandong First Medical University

    Shandong, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.